RIDA qLine® Allergy quality assessment: Register now!
R-Biopharm starts RIDA qLine® Allergy External Quality Assessment. This new tool will help to ensure the quality of the testing procedures in laboratories using RIDA qLine® Allergy and the [...]
Safe into the upcoming influenza season with RIDA®GENE real-time PCR assays
The RIDA®GENE real-time PCR assays (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) successfully detected the suggested vaccination strains for influenca of the 2015/2016 season.
Inflammatory bowel disease – TNFalpha blocker treatment and calprotectin
Chronic inflammatory bowel disease (IBD) is characterized by recurring and often ongoing flares. The most common forms of IBD are Crohns disease and Ulcerative colitis.
TNFalpha blocker and drug monitoring
TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as [...]
Calprotectin predicts relaps after stopping TNFα treatment
Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.
Drug monitoring reduces Infliximab treatment costs
Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.
Influenza season 2015 dominated by new influenza A variant (H3N2)
The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).
Drug monitoring of infliximab biosimilars
Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.
Legionella and mycoplasma pneumoniae: New RIDA®GENE products for detection of atypical CAP bacteria
Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]
Therapeutic drug monitoring of Infliximab
RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma.